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Prostate cancer represents the most frequent non-cutaneous neoplasia in males. This type of neoplasia can develop peculiar patterns of evolution, presenting, in many 
cases, precocious relapses and metastasis. Bone metastasis in the mouth is extremely 
rare, and represents 1% of all malignant mouth neoplasias. The aim of the present study 
is to report a clinical case of bone metastasis in the mandibular region associated with a 
tumoral prostate adenocarcinoma, as well as to discuss connected aspects about diagnosis, 
prognosis and integrated treatment of this condition.
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INTRODUCTION
Prostate cancer represents the most frequent 
non-cutaneous neoplasia in males, corresponding 
to 40% of the cases, being the second death cause 
due to malignant tumors in men. The incidence as 
much as the mortality increases exponentially after 
50 years of age5,9,10.
This type of neoplasia can develop peculiar 
patterns of evolution, presenting, in many cases, 
precocious relapse and metastasis. Of a total of 
patients who have received curative treatment for 
the localized prostate cancer, 30% relapse. The 
most frequent is the bone metastasis, generally 
multiple, mainly reaching the vertebral column, 
shoulder joints and sacroiliac bone. Among these 
patients, survival generally varies from 20 to 30 
months5,10.
Bone metastasis in the mouth is extremely 
rare, and represents 1% of all malignant mouth 
neoplasias. The incidence is 80 to 90% in the 
mandible, mainly in the molar region and it always 
sign the spreading of the cancer illness. It originates 
from primary malignant neoplasias located mainly 
in the breast, prostate, lung, thyroid and kidney. 
However, the occurrence of prostate and kidneys 
as primary fields for jaw’s metastasis through blood 
pathways are considered extremely rare1,16. Among 
the bone metastases affecting the oral cavity, 
adenocarcinoma is the most frequent histological 
type1,16,23.
The main clinical manifestations may include 
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pain, swelling, tooth loss, bleeding, trismus, 
paresthesia sensation (often associated with 
inferior alveolar nerve involvement) and epistaxis19. 
Included in the differential diagnosis of metastatic 
peripheral lesions on the gingiva or alveolar ridge 
are pyogenic granuloma, peripheral giant cell 
granuloma and, possibly, peripheral ossifying 
fibroma or ulcerated fibroma6. The difficulty of 
clinical identification and differentiation between 
primary lesions and metastatic lesions of the jaw 
make the biopsy with histopathological analysis 
(combined with immunohistochemistry) mandatory 
for diagnosis1.
Besides representing great importance for 
public health, this issue becomes fundamental for 
a multidisciplinary evaluation of the patient.
CASE REPORT
Male patient, white, 54 years old, was admitted 
in the Oral and Maxillofacial Trauma and Surgery 
Team at Hospital de Base de Bauru (Bauru Base 
Hospital), in March 2009. The patient’s main 
complaint was pain in the left mandibular region 
above the median line and paresthesia of the 
anatomical areas sensitized by the Left Alveolar 
Inferior Nerve, branch of the Mandibular Nerve 
and Trigeminal Nerve. The first signal related 
by the patient was a pathology originated from 
a root treatment about one year before, which 
developed a mandibular abscess clinically treated. 
Once healed from this abscess, chronic pain 
persisted in half mandible associated with localized 
paresthesia. Because of the posterior absence of 
dental symptoms even as mandibular pain and 
face paresthesia, the clinical dentist referred the 
patient to the one who suggested the diagnosis of 
Trigeminal Neuralgia, establishing treatment with 
Carbamazepin 200 mg and Gabapentin 300 mg, 
both once a day, that lasted about 1 year or more.
The patient’s medical history revealed 
pharmacologically controlled diabetes and prostate 
acinar adenocarcinoma Gleason score 7 (3+4), 
with initial PSA score on 4.78. This latter treated in 
2005 by means of radical prostatectomy performed 
in January 2006 (pT3N0M0), having follow-up 
procedures with urology, but in a random and 
intermittent manner, a history not explored or 
valued by neurology.
Physical examination revealed left mandibular 
bulging in the buccolingual aspect and tooth 
mobility involving bulging region extending to the 
opposite canine tooth associated with a slight gums 
erythema, but without symptoms compatible with 
periodontal disease. In addition, we observed the 
absence of pathognomonic signs and symptoms 
of classic Trigeminal Neuralgia, showing no 
intermittent pain, neither specific localized pain 
spots (trigger-points). Based on this clinical 
symptomatology, we established a hypothesis of 
diagnosis as osteomyelitis and/or cancer, not yet 
discarding the possibility of Atypical Neuralgia of 
the Trigeminal Nerve (Figure 1).
Through a radiography exam, it was possible 
to define a mild, diffuse radiolucency in the left 
mandibular body. The Computed Tomography Scan 
showed an anatomical structure alteration with 
osteolysis areas in the premolars, molars and in the 
left region of the chin (Figures 2 and 3).
Because of that, we carried out an incisional 
biopsy and culture/antibiogram of sensitivity of the 
affected area. The results showed adenocarcinoma 
(clear cell type) with necrosis areas and infiltrating 
bone and soft tissue. The isolated microorganism 
was Staphylococcus aureus. These findings suggest 
Figure 1- Clinical aspect of the patient. It is possible to see 
the bulging involving left buccolingual region of premolars 
and molars. Source: Oral and Maxillofacial Surgery team 
– Bauru Base Hospital Association
Figure 2- Panoramic radiography showing diffuse 
radiolucent area in the left mandibular body region. 
Source: Oral and Maxillofacial Surgery team – Bauru 
Base Hospital Association
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a metastatic tumor infected by via hematogenous 
route. The tumor had no communication between 
the internal and external environment, without skin 
or mucosa fistula, confirmed by whole-body bone 
scintigraphy with special interest in the mandibular 
region, where increased uptake of the radiocontrast 
agent was observed, as well as in many areas, 
such as the right clavicle and scapula, humerus, 
ribs, spine, sternum, hip bone and femur (right/
left) (Figure 4).
After confirming a definitive diagnosis, the patient 
was taken to the Oncology Clinic, where in May 2009 
Figure 3- Computed tomography showing areas of osteolysis in the left mandibular body and symphysis region. Source: 
Oral and Maxillofacial Surgery team – Bauru Base Hospital Association
Figure 4- Whole-body bone scintigraphy, increased uptake of the radiocontrast agent observed in the mandibular region, 
right clavicle and scapula, humerus, ribs, spine, sternum, hip bone and femur (right/left). Source: Oral and Maxillofacial 
Surgery team – Bauru Base Hospital Association
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was admitted to the Clinical Oncology Department 
with a metastatic bone disease diagnosis (prostate 
acinar adenocarcinoma) confirmed by three 
different methods: bone scintigraphy, incisional 
biopsy and immunohistochemical analysis of 
mandibular lesions. The treatment consisted of 
the use of goserelin acetate (3.6 mg/month) and 
bisphosphonate (clodronate, 4 ampoules/month). 
The patient was evaluated as having good disease 
control and good tolerance to treatment for 
some months, when disseminated neoplasm and 
pulmonary involvement led to a lethal outcome, 
with the patient’s death in less than a year.
DISCUSSION
Prostate cancer is a silent disease; the 
findings show that the prevalence of histological 
malignancy exceeds the clinically manifest disease 
in approximately eight times. According to the 
American Cancer Society, for early cancer detection 
in individuals without symptoms, it is recommended 
the digital rectal exam and PSA dosage annually for 
individuals over age 50 or 45 for men belonging to 
risk groups18.
The PSA is a kallikrein family protease, produced 
by the prostate epithelium, whose function is to 
solubilize the sperm after ejaculation. The accepted 
level as the upper limit of normal PSA is 4 ng/ml18. 
The PSA has a great clinical utility; it serves for 
early detection of prostate cancer, cancer staging, 
prognostic assessment and therapeutical response 
control3.
In addition to the PSA level in case of established 
disease, it is necessary to evaluate the prostate 
cancer advancement by image exams [transrectal 
ultrasound, bone scintigraphy, chest radiography, 
computed tomography of the abdomen and pelvis, 
magnetic nuclear resonance of the abdomen and 
pelvis, and positron emission tomography (PeT)] 
to define the appropriate therapeutical strategy. In 
order to classify neoplastic levels, some methods 
are used to analyze the histological grade (Gleason 
score), tumor volume and stage at the diagnosis 
time12-14,16.
When the primary tumor volume is less than 
3 ml, metastasis rarely occurs. When the present 
volume is greater than 12 ml metastasis is almost 
always present5,16. According to McNeal11(1992), 
only tumors larger than 1 cm in diameter (volume 
of 0.5 ml) are capable of extracapsular extension. 
The lymph nodes or seminal vesicles spread are 
usually more common in tumors larger than 2 cm 
in diameter11.
The Gleason system has been introduced to 
aid on the tumor evolution prediction and the 
pathological staging by transrectal biopsy or of 
the surgical specimen itself. The lesions with 
Gleason score 2-4 (well differentiated) have a 
more indolent behavior, whereas the ones scoring 
7-10 (undifferentiated) are aggressive, responding 
poorly to various treatment options6.
The clinical staging of tumors, TNM classification, 
has been adopted to characterize tumors, helping 
in choosing the most appropriate therapy and to 
estimating the patients’ survival chances. This 
system evaluates the primary tumor, regional lymph 
nodes and distant metastases19.
The patients’ selection for specific treatments is 
usually done through the risk of tumor recurrence and 
dissemination subdivision. Among the therapeutical 
modalities there are clinical observation, surgery, 
radiotherapy, chemotherapy, hormonal therapy and 
combination therapy.
Rutsatz, et al.17 (1990) in a period of 35 
years, reported 1008 patients with craniofacial 
malignancies, found only five patients (0.5%) with 
metastatic tumors to the jaw, from different primary 
sites. Van der Waal, et al.23 (2003), identified 
adenocarcinoma as the primary histological type 
responsible for gnathic bone metastases, starting 
from different locations of primary tumors, 
confirming the reported case.
The four most common tumor sites that 
metastasize to the man jaws, in descending order of 
frequency, are lung, prostate, kidney and liver and, 
in women, breast, adrenal gland, female genital 
organs (uterus, cervix, ovaries) and colorectum. In 
the first decade of life, tumors of the adrenal gland 
(neuroblastoma) most frequently spread to the jaws 
and in the second decade, bone primaries prevail 
(osteosarcoma, ewing’s/PNeT)8. Most patients with 
oral metastasis, generally have the primary cancer 
well diagnosed, confirming the reported case in 
which the primary tumor was treated years before 
by radical prostatectomy and the patient was still 
on medical care during the gnathic metastasis. In 
25-35% of cases, the presence of metastasis on 
the head and neck is the first sign of disseminated 
malignant disease, and in about 70% of cases, 
metastatic lesions are diagnosed in conjunction 
with the primary focus. Sometimes, however, the 
diagnosis of the primary lesion may be difficult or 
even impossible2,21.
Multidisciplinary work is recommended in the 
care of patients with malignant neoplasms or 
neurological disorder of doubtful identification in 
order to provide diagnosis, planning and treatment 
that offer the most favorable prognosis.
Piattelli, et al.15 (1999) conducted a survey of 
390 oral cancer cases, of which 22 cases (5.6%) 
were metastatic tumors on gnathic bones from 
other regions, being prostate gland the primary site 
of these tumors, as occurred in our case.
In cases of metastatic bone illness, the pain and 
pathological fractures are prevalent manifestations, 
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although the condition is asymptomatic in some 
patients. In this case, the patient reported the 
presence of chronic pain in hemi mandible, including 
a localized paresthesia, symptoms that were initially 
treated as Trigeminal Neuralgia. However, by 
conducting special examinations, we obtained the 
diagnosis of metastatic adenocarcinoma prostate 
cancer in the lung and bone, involving, in addition 
to the cited organs, the mandibular region. Bone 
tumor involvement of the oral region is higher 
compared to the soft tissue. Metastatic disease in 
the jaws may also affect the adjacent soft tissues 
and present as dental or periodontal infection20. 
When the metastasis is located in the jaw, the 
primary neoplasm is more likely to develop bone 
metastases, especially in the molar region1. It is 
believed that the greatest amount of cancellous 
bone present in the region is the reason for the 
higher frequency of involvement when compared 
to other facial bones, as trabecular bone presents 
growth factors that improve the neoplasia spread, 
confirming the reported case in which bone 
metastasis reached the region of the body and the 
mandibular symphysis8.
The unilateral paresthesia type, as occurred 
in this case, hypoesthesia or anesthesia of the 
lower lip, known as Numb Chin Syndrome with or 
without the presence of pain, may be the initial 
clinical manifestation of a significant percentage 
that manifests on the jaw. Alterations in sensitivity 
involving the lower lip, even without significant 
radiological changes, should alert the expert to 
think about the possibility of an initial metastasis1,21. 
For an accurate diagnosis and treatment of this rare 
condition, detailed and careful evaluation of the 
clinical picture, associated with a high degree of 
suspicion, is needed, requiring a multidisciplinary 
approach to the case8,21.
The prognosis of these patients is reserved for 
the pathophysiology of the primary tumor. Usually, 
with minimal cellular differentiation they may 
render the initial site location. In addition, bone 
metastases are associated with advanced disease 
and in some cases may be involved in malignant 
lesions - which may lead the patient to death, as 
reported in this case7.
The radiation treatment can be considered 
curative regarding single oral metastases whose 
primary focus is clearly identified and which 
responded well to therapy. However, most authors 
consider an unfavorable prognosis for most cases of 
this oral cancer2. Surgical treatment in most cases is 
not recommended, indicating palliative therapy. The 
cases that may have a better indication are those 
with localized metastases, with no other identified 
metastasis and controlled primary disease, which 
does not occur in our case, since the examination 
of bone scintigraphy identified multiple metastatic 
tumors distributed throughout the body, palliative 
therapy being considered the best alternative14.
Chemotherapy is indicated only in metastatic 
disease refractory to hormonal treatment, as in 
cases of predominance of hormone-independent cell 
clones or progressive increase in serum PSA22. The 
use of bisphosphonates, as reported in the present 
case, is justified in the presence of bone metastases 
and when refractory to hormonal treatment, despite 
the risk of complications related to these drugs, 
such as osteonecrosis. There is an interesting 
indication to the use of these drugs as this therapy 
provides control of the neoplastic disease and also a 
relative patient survival chance4. In advanced cases, 
the quality of life, despite the patients having no 
chance of cure for the disease, is the main objective, 
providing less pain and discomfort17.
FINAL CONSIDERATIONS
Metastatic lesions are related to the advanced 
stage of the disease and usually with a high 
degree of histological aggressiveness. This fact 
explains the difficulty of curative treatment, and 
these injuries are usually classified as reserved 
and dark prognosis. It is important to emphasize 
the relevance of detailed clinical examination and 
multidisciplinary evaluation in order to establish the 
differential diagnosis and so the correct treatment.
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